Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc.
On March 9, 2025, Bronstein, Gewirtz & Grossman, LLC, a prominent national law firm, announced the filing of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) and certain of its officers. The lawsuit alleges that Regeneron and its officers violated the federal securities laws during the Class Period, which spans from November 2, 2023, to October 30, 2024.
Class Definition
This lawsuit, filed in the United States District Court for the Southern District of New York, aims to recover damages for all persons and entities that purchased or otherwise acquired Regeneron securities during the Class Period. The lawsuit alleges that Regeneron made materially false and misleading statements regarding its business, operations, and financial condition.
Allegations Against Regeneron
According to the complaint, Regeneron made false and misleading statements regarding its business, including:
- The commercial success of its Eylea product
- The potential for its pipeline products
- Its financial outlook and revenue growth
- The impact of regulatory actions on its business
The complaint alleges that Regeneron’s statements were misleading because they failed to disclose material adverse information, including:
- Weakness in sales of Eylea
- Issues with its pipeline products
- Decreased revenue growth
- Regulatory setbacks
Impact on Individual Investors
If you purchased Regeneron securities during the Class Period, you may be eligible to participate in this class action lawsuit. The lawsuit seeks to recover damages for investors who suffered financial losses as a result of Regeneron’s alleged securities law violations. You may contact the firm to discuss your legal options.
Impact on the World
The impact of this class action lawsuit on the world may include increased scrutiny of Regeneron’s business practices and financial reporting. It may also lead to changes in the way the company communicates with investors and regulators. Additionally, the lawsuit could result in financial losses for Regeneron and its officers, potentially impacting the company’s ability to invest in research and development or make strategic acquisitions.
Conclusion
Bronstein, Gewirtz & Grossman, LLC’s announcement of a class action lawsuit against Regeneron Pharmaceuticals, Inc. alleging securities law violations during the Class Period has significant implications for both individual investors and the wider world. The lawsuit seeks to recover damages for investors who purchased Regeneron securities during the Class Period and suffered financial losses as a result of the alleged misrepresentations. The impact of the lawsuit on Regeneron and its officers remains to be seen, but it is clear that increased scrutiny of the company’s business practices and financial reporting is warranted.
If you purchased Regeneron securities during the Class Period and believe you may be eligible to participate in this class action lawsuit, contact Bronstein, Gewirtz & Grossman, LLC to discuss your legal options. The firm is dedicated to ensuring that investors receive the compensation they deserve.
